Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome.
OBJECTIVE
Probiotics are live organisms that survive passage through the gastrointestinal tract and have beneficial effects on the host. Lactobacillus and Bifidobacterium have been recommended for cholesterol lowering, acute diarrhea, prevention of cancer, or inflammatory bowel disease. On the other hand, after massive bowel resection, bacterial overgrowth is frequent and favors bacterial translocation (BT). The possible beneficial effects of Bifidobacterium lactis (BL) administration on BT in experimental short bowel syndrome (SBS), have not been investigated. The aim of this study was to test the hypothesis that BL administration decreases BT in SBS in animals fed orally.


METHODS
One hundred twenty-eight adult Wistar rats fed orally with standard rat chow and tap water "ad libitum" were maintained in individual metabolic cages for 10 days and divided into 3 groups: control group (n = 71): nonmanipulated animals; RES group (n = 39): 80% gut resection from 10 cm beyond the angle of Treitz to 10 cm above the cecum; RES-PRO group (n = 18): same resection and daily 7.8 x 10(8) CFU B Lactis administration, after orogastric intubation. At the end of the experiment they were killed, and mesenteric lymph nodes (MLN) and peripheral and portal blood specimens were recovered and cultured. Bacterial identification in blood was made by conventional methods, and MLN culture was considered positive with a growth over 100 CFU/g.


RESULTS
Bacterial translocation was detected in 6% of control group rats. The incidence of BT in the RES group was 87% (34 of 39), whereas only 50% (9 of 18) of RES-PRO animals had BT (P <.05). The relative risk reduction (RRR) was 0.43 (95% Cl 0.14 to 0.72), and the number needed to treat (NNT) was 3 (95% Cl 2 to 8). In other words, animals that received BL had the risk of BT reduced by 43% (RRR of 0.43), and of every 3 animals treated, 1 is expected to be free of BT (NNT of 3).


CONCLUSIONS
Administration of B Lactis reduces the incidence of BT in adult Wistar rats after 80% gut resection.
Eizaguirre
I
I
San Sebastian, Spain. ieizagui@chdo.osakidetza.net
Urkia
N Garcia
NG
Asensio
A B
AB
Zubillaga
I
I
Zubillaga
P
P
Vidales
C
C
Garcia-Arenzana
J M
JM
Aldazabal
P
P
D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects*; D001644:Bifidobacterium; D006088:Gram-Negative Aerobic Bacteria / Q000502:physiology*; D019936:Probiotics / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D012778:Short Bowel Syndrome / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology